Affimed

About:

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

Website: https://www.affimed.com/

Twitter/X: affimed

Top Investors: OrbiMed, Roche, Novo Nordisk, Perceptive Advisors, Novo Holdings

Description:

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Total Funding Amount:

$534M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Heidelberg, Baden-Wurttemberg, Germany

Founded Date:

2000-01-01

Contact Email:

info(AT)affimed.com

Founders:

Melvyn Little

Number of Employees:

51-100

Last Funding Date:

2022-04-13

IPO Status:

Public

© 2025 bioDAO.ai